MedTrace Logo

Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

NCT04519944 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 666

Last updated 2023-08-02

No results posted yet for this study

Summary

This study is designed to gain real-world clinical data on the peri- and post-procedural usage of anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation (NVAF) undergoing successful percutaneous coronary intervention (PCI) treated with edoxaban.

Conditions

  • Non-valvular Atrial Fibrillation

Interventions

DRUG

Edoxaban

This is an observational, prospective study; no treatment will be administered.

Sponsors & Collaborators

  • Daiichi Sankyo Deutschland GmbH

    collaborator UNKNOWN

  • Daiichi Sankyo

    lead INDUSTRY

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-30
Primary Completion
2023-07-06
Completion
2023-07-06
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04519944 on ClinicalTrials.gov